Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
13 avr. 2022 17h10 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company with the mission to improve patient outcomes by...
Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022
11 avr. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
28 mars 2022 08h00 HE
|
Oncocyte Corporation
Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer IRVINE, Calif., March 28, 2022 ...
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
10 mars 2022 16h05 HE
|
Oncocyte Corporation
DetermaRx Revenues and Test Volume Grew 104% and 54%, respectively, in Q4 versus Q3 2021 Development and Co-Marketing Agreement with Thermo Fisher Scientific to Provide Platform and Channel Partner...
Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10
01 mars 2022 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient...
Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
10 févr. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology
18 janv. 2022 16h05 HE
|
Oncocyte Corporation
Collaboration extends global reach for Thermo Fisher’s rapid next-generation sequencing technology Conference call to be held today at 4:30 pm ET/1:30 pm PT IRVINE, Calif., Jan. 18, 2022 (GLOBE...
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer
04 janv. 2022 08h00 HE
|
Oncocyte Corporation
Data show DetermaCNI detects recurrence with higher sensitivity than standard of care biomarkers, high sensitivity with very low false positives DetermaCNI is the first clinical-grade test to monitor...
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer
09 déc. 2021 18h00 HE
|
Oncocyte Corporation
Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer DetermaIO...
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China
08 déc. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that...